Early Detection of OAB and Elimination of Negative Impact on Quality of Life
NCT07371000 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2026-01-27
Summary
Overactive bladder (OAB) is one of the most common health problems in the adult population. The goal of this project is to improve the awareness of the problem and to correctly refer the targeted persons to a specialist or a doctor. This will be provided by an online screening tool, designed as web platform and mobile application, where the data will be stored in respect to GDPR. People with a positive result from the online screening tool will be offered an examination by a specialist (gynaecologist, urogynaecologist, urologist) involved in the project. The specialist will have access to the results from the online screening tool - he/she will log into the web platform with a view of the participants profile. He/she will perform the diagnosis, confirm or refute the diagnosis and complement it with any further diagnostic tests and set the standard treatment.
Conditions
- Overactive Bladder (OAB)
Interventions
- OTHER
-
Standardized Screening Protocol
After completing the online screening tool (including validated questionnaires), selected participants are offered an appointment with a specialist who will perform a diagnosis, confirm or rule out OAB and set up adequate therapy according to recommended procedures.
Sponsors & Collaborators
-
General University Hospital, Prague
collaborator OTHER -
Institute of Health Information and Statistics of the Czech Republic
lead OTHER_GOV
Principal Investigators
-
Jaromír Mašata, Professor · General University Hospital of Prague
Study Design
- Allocation
- NA
- Purpose
- SCREENING
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-01
- Primary Completion
- 2026-06-30
- Completion
- 2026-08-31
Countries
- Czechia
Study Locations
More Related Trials
-
Overactive Bladder Education
NCT02505607 ·Status: TERMINATED ·Phase: NA
-
Comparative Urine Proteomic Studies of Overactive Bladder in Humans
NCT01367886 ·Status: COMPLETED ·Phase: NA
-
Urinary Biomarkers in Overactive Bladder in Children
NCT02704013 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
NCT05162833 ·Status: COMPLETED ·Phase: NA
-
Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
NCT02024945 ·Status: COMPLETED
-
Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions
NCT02197533 ·Status: COMPLETED ·Phase: NA
-
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 ·Status: COMPLETED
-
Experience Sampling Method in OAB Patients
NCT03435991 ·Status: UNKNOWN
-
TPTNS: Home vs Hospital Treatment for Overactive Bladder
NCT03727711 ·Status: UNKNOWN ·Phase: NA
-
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
NCT02320773 ·Status: COMPLETED
-
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 ·Status: COMPLETED ·Phase: PHASE3
-
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231 ·Status: COMPLETED
-
Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
NCT00313924 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
NCT03903094 ·Status: COMPLETED
-
Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
NCT03251300 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
NCT00742833 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
NCT01317810 ·Status: WITHDRAWN
-
Bladder Overactivity and Post-Botulinum Toxin Telemonitoring
NCT07379372 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
NCT03602508 ·Status: COMPLETED
-
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
NCT05211193 ·Status: COMPLETED
-
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of ONO-8539 in Patients With Overactive Bladder
NCT00876421 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
NCT01029015 ·Status: COMPLETED
-
Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
NCT01003405 ·Status: WITHDRAWN ·Phase: PHASE3